scispace - formally typeset
G

Göran Karlsson

Researcher at University of Florence

Publications -  10
Citations -  1092

Göran Karlsson is an academic researcher from University of Florence. The author has contributed to research in topics: Liposome & Vesicle. The author has an hindex of 10, co-authored 10 publications receiving 1048 citations. Previous affiliations of Göran Karlsson include University of Bayreuth & University of British Columbia.

Papers
More filters
Journal ArticleDOI

A New Double-Responsive Block Copolymer Synthesized via RAFT Polymerization: Poly(N-isopropylacrylamide)-block-poly(acrylic acid)

TL;DR: In this article, double-responsive block copolymers in solution were investigated by dynamic light scattering, temperature-sweep NMR, cryogenic transmission electron microscopy, and IR spectroscopy.
Journal ArticleDOI

Self-Assembly of β-Cyclodextrin in Water. Part 1: Cryo-TEM and Dynamic and Static Light Scattering

TL;DR: A critical aggregation concentration between 2 and 3 mM was determined by using dynamic (DLS) and static (SLS) light scattering to investigate the presence of β-cyclodextrin aggregates in water.
Journal ArticleDOI

Morphological changes induced by phospholipase C and by sphingomyelinase on large unilamellar vesicles: a cryo-transmission electron microscopy study of liposome fusion.

TL;DR: The fact that the same honeycomb intermediate can lead to vesicle fusion or to a cubic phase is taken in support of the hypothesis according to which a highly curved lipid structure ("stalk") would act as a structural intermediate in membrane fusion.
Journal ArticleDOI

Synthesis, liposomal preparation, and in vitro toxicity of two novel dodecaborate cluster lipids for boron neutron capture therapy.

TL;DR: The zeta-potential measurements indicate that both B- 6-14- and B-6-16-containing vesicles are negatively charged, with the most negative potential described of any liposome so far.
Journal ArticleDOI

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.

TL;DR: Assessment of the attributes of a liposome formulation required to significantly increase the plasma levels of idarubicin and whether increases in the circulation longevity of the drug mediate improved antitumor activity are established, and effectiveness studies demonstrated that neither the free nor liposomal formulation of IDA was therapeutically active.